Intra-Cellular Therapies, Inc. 8-K Filing: Key Insights & Updates

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Entity Information:

• Company Name: Intra-Cellular Therapies, Inc.
• CIK Number: 0001567514
• SEC File Number: 001-36274
• EIN: 36-4742850
• Address: 135 Route 202/206 Suite 6, Bedminster, NJ 07921
• Contact Number: (646) 440-9333

2. Filing Details:

• Filing Type: 8-K (which is used to report major events that shareholders should know about)
• Filing Date: January 10, 2025

3. Stock Information:

• Common Stock Ticker Symbol: ITCI
• Exchange: NASDAQ

4. Reporting Period:

• Start Date: January 10, 2025
• End Date: January 10, 2025

5. XBRL and XML Details:

• The document is structured in XBRL format, which is used for the electronic communication of financial data.
• Schema reference is indicated with a link to "itci-20250110.xsd".

Insights:

• Intra-Cellular Therapies, Inc. is actively reporting significant events through an 8-K filing as of the date mentioned.
• The company's common stock is publicly traded on NASDAQ under the ticker symbol ITCI.
• The information indicates that the company is compliant with SEC reporting requirements, making it transparent to investors and stakeholders.

This snapshot provides a concise overview of the company's financial reporting context and key identifiers.